BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, Schmitz J, Schwarz A, Ivanyi P, Steinmetz OM, Reinhard L, Hoxha E, Zipfel PF, Bräsen JH, Wiech T. Bevacizumab-associated glomerular microangiopathy. Mod Pathol 2019;32:684-700. [PMID: 30552416 DOI: 10.1038/s41379-018-0186-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Kalla S, Ellis RJ, Campbell SB, Doucet B, Isbel N, Tie B, Jegatheesan D. Thrombotic Microangiopathy Associated with Pazopanib in a Kidney Transplant Recipient. J Kidney Cancer VHL 2021;8:25-31. [PMID: 33850692 DOI: 10.15586/jkcvhl.v8i1.161] [Reference Citation Analysis]
2 Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. Clin Exp Nephrol 2021. [PMID: 34115234 DOI: 10.1007/s10157-021-02090-z] [Reference Citation Analysis]
3 Nihei S, Asaka J, Takahashi H, Kudo K. Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro. Int J Nephrol 2021;2021:8381115. [PMID: 34912580 DOI: 10.1155/2021/8381115] [Reference Citation Analysis]
4 Tanabe K, Wada J, Sato Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat Rev Nephrol 2020;16:289-303. [PMID: 32144398 DOI: 10.1038/s41581-020-0260-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
5 Van Wynsberghe M, Flejeo J, Sakhi H, Ollero M, Sahali D, Izzedine H, Henique C. Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics (Basel) 2021;11:640. [PMID: 33916159 DOI: 10.3390/diagnostics11040640] [Reference Citation Analysis]
6 Mizuno S, Kitayama C, Sanada S, Sato T. Bortezomib-induced glomerular microangiopathy complicated with monoclonal immunoglobulin deposition disease. CEN Case Rep 2021. [PMID: 33909224 DOI: 10.1007/s13730-021-00603-z] [Reference Citation Analysis]
7 Katsuno T, Ito Y, Kagami S, Kitamura H, Maruyama S, Shimizu A, Sugiyama H, Sato H, Yokoyama H, Kashihara N. A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 2020;24:789-97. [PMID: 32415379 DOI: 10.1007/s10157-020-01896-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Frazier KS. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies. Toxicol Pathol 2022;:1926233221100414. [PMID: 35608030 DOI: 10.1177/01926233221100414] [Reference Citation Analysis]
9 Demir F, Troldborg A, Thiel S, Lassé M, Huesgen PF, Tomas NM, Wiech T, Rinschen MM. Proteolysis and inflammation of the kidney glomerulus. Cell Tissue Res 2021. [PMID: 33864499 DOI: 10.1007/s00441-021-03433-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Touzani F, Geers C, Pozdzik A. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury. Case Rep Nephrol 2019;2019:2919080. [PMID: 31934470 DOI: 10.1155/2019/2919080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 Gökyer A, Küçükarda A, Köstek O, Hacıoğlu MB, Uzunoğlu S, Kula O, Kurt N, Üstündağ S, Erdoğan B, Çiçin İ. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study. Int J Clin Oncol 2020;25:1757-62. [PMID: 32591963 DOI: 10.1007/s10147-020-01729-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ebrahimi M, Balibegloo M, Rezaei N. Monoclonal antibodies in diabetic retinopathy. Expert Rev Clin Immunol 2022. [PMID: 35105268 DOI: 10.1080/1744666X.2022.2037420] [Reference Citation Analysis]
13 Morimoto M, Arai T, Matsuura M, Ono Y. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer. CEN Case Rep 2021;10:6-11. [PMID: 32642991 DOI: 10.1007/s13730-020-00504-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]